Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31087073 | 1.00 | GPR119 (0.48) | GPR119HDAC1NR1H2NR1H3CHRM5 | |
| SCHEMBL19990317 | 1.00 | GPR119 (0.48) | GPR119HDAC1NR1H2NR1H3CHRM5 | |
| SCHEMBL31087051 | 0.89 | GPR119 (0.47) | GPR119HDAC1NR1H2NR1H3CHRM5 | |
| SCHEMBL24963028 | 0.87 | GPR119 (0.47) | GPR119NR1H2NR1H3CHRM1CHRM3 | |
| SCHEMBL29165873 | 0.87 | GPR119 (0.47) | GPR119NR1H2NR1H3CHRM1CHRM3 | |
| SCHEMBL31087035 | 0.86 | GPR119 (0.46) | GPR119HDAC1NR1H2NR1H3MAPT | |
| SCHEMBL1448125 | 0.85 | GPR119 (0.61) | GPR119HDAC1NR1H2NR1H3CHRM5 | |
| SCHEMBL12740848 | 0.85 | GPR119 (0.61) | GPR119HDAC1NR1H2NR1H3CHRM5 | |
| SCHEMBL1448124 | 0.85 | GPR119 (0.61) | GPR119HDAC1NR1H2NR1H3CHRM5 | |
| SCHEMBL18149393 | 0.83 | ACACB (0.42) | CHRM5CHRM1CHRM3SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | GPR119 976/4885HDAC1 1884/4885NR1H2 1005/4885 |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | TNF, CD40, TNFRSF1A | GPR119 976/4885HDAC1 1884/4885NR1H2 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.